Codiak Biosciences (CDAK) stock price, revenue, and financials

Codiak Biosciences market cap is $373.9 m, and annual revenue was $2.92 m in FY 2020

$373.9 M

CDAK Mkt cap, 08-Sept-2021

$2.9 M

Codiak Biosciences Revenue FY, 2020
Codiak Biosciences Net income (FY, 2020)-91.7 M
Codiak Biosciences EBIT (FY, 2020)-90.9 M
Codiak Biosciences Cash, 31-Dec-202088.9 M
Codiak Biosciences EV347.9 M
Get notified regarding key financial metrics and revenue changes at Codiak BiosciencesLearn more
Banner background

Codiak Biosciences Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

388.0k2.9m

R&D expense

28.5m59.5m74.0m

General and administrative expense

9.9m21.0m19.9m

Operating expense total

46.4m80.5m93.8m

EBIT

(46.4m)(80.2m)(90.9m)

EBIT margin, %

(20658%)(3119%)

Interest expense

300.0k

Interest income

1.4m1.5m253.0k

Income tax expense

Net Income

(44.5m)(78.0m)(91.7m)

EPS

(23.1)(30.7)

Quarterly

USDQ3, 2020

Revenue

954.0k

R&D expense

30.6m

General and administrative expense

5.3m

Operating expense total

36.0m

EBIT

(35.0m)

EBIT margin, %

(3672%)

Interest income

4.0k

Net Income

(35.3m)

Codiak Biosciences Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

18.1m10.3m88.9m

Prepaid Expenses

4.8m

Current Assets

91.1m94.1m93.8m

PP&E

5.9m17.6m31.4m

Total Assets

97.7m116.0m151.3m

Accounts Payable

615.0k2.4m2.0m

Short-term debt

1.5m

Current Liabilities

4.9m19.8m17.7m

Long-term debt

61.5m

Total Debt

63.0m

Total Liabilities

5.6m94.0m136.8m

Common Stock

2.0k

Preferred Stock

201.0m214.8m

Additional Paid-in Capital

2.0k2.0k302.7m

Retained Earnings

(109.0m)(192.9m)(288.1m)

Total Equity

(109.0m)(192.8m)14.6m

Financial Leverage

-0.9 x-0.6 x10.4 x

Quarterly

USDQ2, 2020Q3, 2020

Cash

50.9m48.3m

Prepaid Expenses

4.0m

Current Assets

52.6m52.4m

PP&E

31.1m31.5m

Total Assets

110.3m110.4m

Accounts Payable

2.1m2.5m

Short-term debt

1.8m

Current Liabilities

18.7m34.4m

Long-term debt

61.9m

Total Debt

63.7m

Total Liabilities

123.6m154.4m

Preferred Stock

221.6m225.0m

Additional Paid-in Capital

2.0k1.1m

Retained Earnings

(234.8m)(270.1m)

Total Equity

(234.8m)(269.1m)

Financial Leverage

-0.5 x-0.4 x

Codiak Biosciences Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

(44.5m)(78.0m)(91.7m)

Depreciation and Amortization

1.7m2.8m4.4m

Accounts Payable

(536.0k)1.5m(378.0k)

Cash From Operating Activities

(30.6m)(1.7m)(63.4m)

Purchases of PP&E

(1.8m)(10.5m)(21.1m)

Cash From Investing Activities

(78.5m)(11.7m)52.0m

Cash From Financing Activities

(58.0k)9.8m89.6m

Net Change in Cash

(109.2m)(3.6m)78.2m

Interest Paid

155.0k1.4m

Quarterly

USDQ2, 2019Q2, 2020Q3, 2020

Net Income

(35.7m)(38.4m)(73.7m)

Depreciation and Amortization

1.0m2.0m3.1m

Accounts Payable

(168.0k)

Cash From Operating Activities

27.3m(14.4m)(29.5m)

Purchases of PP&E

(2.4m)(18.1m)(19.9m)

Cash From Investing Activities

(3.6m)(55.0m)53.2m

Cash From Financing Activities

254.0k104.0k14.0m

Net Change in Cash

24.0m40.6m37.7m

Interest Paid

458.0k834.0k

Codiak Biosciences Ratios

USDFY, 2018

Financial Leverage

-0.9 x

Codiak Biosciences Operating Metrics

Q2, 2020

Products

11

Discovery Stage Products

7

Pre-Clinical Phase Products

2

Phase II Trials Products

2

Codiak Biosciences Employee Rating

46 votes
Culture & Values
3
Work/Life Balance
4
Senior Management
3
Salary & Benefits
5
Career Opportunities
3
Source